Pfizer: High Yield, Healthy Cash Flow, Catalysts Lining Up - A Mid-Term Long Trade
Pfizer's combination of strong free cash flow, a 6.1% yield, recent regulatory wins and an upgraded revenue outlook make the stock a pragmatic swing trade. We'll lay out an entry, target and stop with a mid-term horizon and the risks that could derail the setup.